Advertisement Insulet proposes secondary offering - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Insulet proposes secondary offering

Insulet has filed a registration statement relating to an underwritten public offering of 4.89 million shares of its common stock, all of which are being sold by selling stockholders.

Medical device maker Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any proceeds from the sale of shares by the selling stockholders.

JP Morgan Securities and Merrill Lynch, Pierce, Fenner & Smith will serve as joint book-running managers, and Leerink Swann & Co, Thomas Weisel Partners and Canaccord Adams will serve as co-managers for the proposed offering.